Virax Current Deferred Revenue vs Total Current Liabilities Analysis
| VRAX Stock | USD 1.94 0.06 3.19% |
Virax Biolabs financial indicator trend analysis is much more than just breaking down Virax Biolabs Group prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Virax Biolabs Group is a good investment. Please check the relationship between Virax Biolabs Current Deferred Revenue and its Total Current Liabilities accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Current Deferred Revenue vs Total Current Liabilities
Current Deferred Revenue vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Virax Biolabs Group Current Deferred Revenue account and Total Current Liabilities. At this time, the significance of the direction appears to have pay attention.
The correlation between Virax Biolabs' Current Deferred Revenue and Total Current Liabilities is -0.76. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Virax Biolabs Group, assuming nothing else is changed. The correlation between historical values of Virax Biolabs' Current Deferred Revenue and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Virax Biolabs Group are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Current Deferred Revenue i.e., Virax Biolabs' Current Deferred Revenue and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | -0.76 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Total Current Liabilities
Total Current Liabilities is an item on Virax Biolabs balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Virax Biolabs Group are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Virax Biolabs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Virax Biolabs Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Virax Biolabs' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.30 in 2024, whereas Selling General Administrative is likely to drop slightly above 2.7 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 15.4K | 15.5K | 26.9K | 28.3K | Depreciation And Amortization | 1.7M | 1.0 | 103.1K | 97.9K |
Virax Biolabs fundamental ratios Correlations
Click cells to compare fundamentals
Virax Biolabs Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.